From the Journals

CBT cost effective for depressed teens refusing antidepressants


 

FROM PEDIATRICS

Brief primary care cognitive-behavioral therapy (CBT) among youth who decline antidepressant therapy appears cost-effective, results of a study found.

“In this study, we demonstrate that brief primary care CBT is a cost-effective treatment option for adolescents with depression and likely generates cost savings over 2 years,” said John F. Dickerson, PhD, of Kaiser Permanente Center for Health Research, Portland, Ore., and his associates

Rawpixel/Thinkstock

Doctor talking with teen girl.

A total of 212 youth with depression (mean age, 15 years) were randomly assigned to treatment as usual (TAU) or TAU plus brief individual CBT. Clinical outcomes included depression-free days and estimated quality-adjusted life-years.

Youth randomly assigned to CBT plus TAU had 26.8 more depression-free days (P = .043) and 0.067 more quality-adjusted life-years (P = .043) on average, compared with patients receiving TAU over a 12-month period. Also, patients in the CBT group had fewer hospitalizations, compared with patients in the TAU group (1.1% vs. 8.8% during 12 months, and 4.4% vs. 12.1% during 24 months), reported Dr. Dickerson and his colleagues.

By the end of the 24-month follow-up, average total costs were $2,811 among youth randomly assigned to CBT plus TAU and $7,354 among youth assigned TAU (adjusted to 2008 U.S. dollars).

“Many adolescents with depression choose to not initiate or continue antidepressant therapy, which limits their options for depression treatment,” the investigators said. “In this evaluation, it is demonstrated that brief, primary care–based CBT is a cost-effective option for the treatment of depression among adolescents with depression who decline or quickly discontinue pharmacotherapy.”

Read more at Pediatrics (2018. doi: 10.1542/peds.2017-1969).

Recommended Reading

Folic acid and multivitamin supplements associated with reduced autism risk
MDedge Family Medicine
Internet addiction ‘an impairing but treatable problem’
MDedge Family Medicine
Early psychotherapy may predict buprenorphine treatment retention
MDedge Family Medicine
Hormone therapy may reduce depressive symptoms in early menopause
MDedge Family Medicine
High levels of neuroinflammatory markers may drive increased Alzheimer’s prevalence among blacks
MDedge Family Medicine
FDA: No more codeine or hydrocodone cold medicines for children
MDedge Family Medicine
Behavioral issues, anorexia may presage celiac disease
MDedge Family Medicine
Young e-cigarette users graduating to the real thing
MDedge Family Medicine
Pathological video game use can be ‘life-dominating’
MDedge Family Medicine
Mood changes reported in cases of methotrexate use for dermatologic disease
MDedge Family Medicine